Cytokinetics Inc [CYTK] stock is trading at $48.53, down -0.86%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The CYTK shares have gain 1.57% over the last week, with a monthly amount drifted -1.16%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Cytokinetics Inc [NASDAQ: CYTK] stock has seen the most recent analyst activity on November 08, 2024, when RBC Capital Mkts initiated its Outperform rating and assigned the stock a price target of $80. Previously, Goldman downgraded its rating to Neutral on August 13, 2024, and dropped its price target to $60. On January 24, 2024, downgrade downgraded it’s rating to Neutral and revised its price target to $92 on the stock. Morgan Stanley downgraded its rating to a Equal-Weight and increased its price target to $90 on January 05, 2024. Goldman initiated its recommendation with a Buy and recommended $50 as its price target on November 09, 2023. B. Riley Securities started tracking with a Buy rating for this stock on November 07, 2023, and assigned it a price target of $66. In a note dated August 15, 2023, SVB Securities initiated an Outperform rating and provided a target price of $58 on this stock.
Cytokinetics Inc [CYTK] stock has fluctuated between $43.53 and $110.25 over the past year. Currently, Wall Street analysts expect the stock to reach $90 within the next 12 months. Cytokinetics Inc [NASDAQ: CYTK] shares were valued at $48.53 at the most recent close of the market. An investor can expect a potential return of 85.45% based on the average CYTK price forecast.
Analyzing the CYTK fundamentals
Cytokinetics Inc [NASDAQ:CYTK] reported sales of 3.22M for the trailing twelve months, which represents a growth of 22.49%. Gross Profit Margin for this corporation currently stands at -28.72% with Operating Profit Margin at -162.98%, Pretax Profit Margin comes in at -179.06%, and Net Profit Margin reading is -179.06%. To continue investigating profitability, this company’s Return on Assets is posted at -0.4, Equity is 3.35 and Total Capital is -0.4. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-48.51.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 47.98 points at the first support level, and at 47.44 for the second support level. However, for the 1st resistance point, the stock is sitting at 49.09, and for the 2nd resistance point, it is at 49.66.
Ratios To Look Out For
For context, Cytokinetics Inc’s Current Ratio is 9.28. As well, the Quick Ratio is 9.28, while the Cash Ratio is 0.43. Considering the valuation of this stock, the price to sales ratio is 1778.64.
Transactions by insiders
Recent insider trading involved WIERENGA WENDALL, Director, that happened on Dec 16 ’24 when 742.0 shares were sold. Director, WENDELL WIERENGA completed a deal on Dec 16 ’24 to buy 742.0 shares. Meanwhile, Director HENDERSON JOHN T sold 1780.0 shares on Dec 11 ’24.
